US20100317737A1 - Topical delivery of l-arginine to cause beneficial effects - Google Patents
Topical delivery of l-arginine to cause beneficial effects Download PDFInfo
- Publication number
- US20100317737A1 US20100317737A1 US12/833,815 US83381510A US2010317737A1 US 20100317737 A1 US20100317737 A1 US 20100317737A1 US 83381510 A US83381510 A US 83381510A US 2010317737 A1 US2010317737 A1 US 2010317737A1
- Authority
- US
- United States
- Prior art keywords
- delivery vehicle
- concentration
- arginine
- weight
- topical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- This invention relates to topical application of a cream, gel, or other vehicle which contains substances such as L-arginine which delivers these substances into tissue for the purpose of producing beneficial effects such as growth of hair on the scalp, healing of leg ulcers secondary to diabetes or confinement to bed and overcoming erectile dysfunction, as well as beneficial effects through restoration of natural mechanisms based on improvement of local blood supply.
- substances such as L-arginine which delivers these substances into tissue for the purpose of producing beneficial effects such as growth of hair on the scalp, healing of leg ulcers secondary to diabetes or confinement to bed and overcoming erectile dysfunction, as well as beneficial effects through restoration of natural mechanisms based on improvement of local blood supply.
- a nitric oxide precursor, L-arginine in its various forms contained in a variety of topical preparations, either by themselves or with other agents to aid in penetration, such as a high ionic strength environment, neutralization of its charge in a complex or by other means, or included in a liposome or other biological carrier, when administered to the scalp causes hair growth, when administered to superficial ulcers causes healing and when administered to the penis enhances erectile function.
- Increasing the levels of concentration of penetrants in combination with reduced amounts of L-arginine maintains effective treatment concentrations.
- a penetrating cream containing L-arginine at an effective concentration and a salt, such as sodium chloride, at a concentration sufficient to create a hostile biophysical environment for the L-arginine in the cream is applied to nightly to the scalp containing a deficit of hair induces hair growth within 3-4 months.
- a penetrating cream containing L-arginine in a concentration sufficient to produce the desired effect along with sodium chloride or other salts at a concentration sufficient to produce a hostile biophysical environment when applied to the penis induces firm and natural erections within 20 minutes.
- the delivery vehicle is a penetrating cream
- the L-arginine is present as L-arginine hydrochloride in a concentration sufficient to produce the desired effect and the agent which creates the hostile biophysical environment is sodium chloride at a concentration sufficient to aid in tissue absorption.
- L-arginine or its derivatives are present in a concentration of 1% to 35%, with preferred concentrations 5% to 35%, and 12% to 35% better.
- the preferred embodiment consists of a base cream with the properties of excellent absorption into the skin which also contains L-arginine hydrochloride (12.5% w/v), choline chloride (10%), sodium chloride (5% w/v) and magnesium chloride (5% w/v).
- the components of the base cream may be those commonly found in hand creams, such as water, mineral oil, glyceryl stereate, squalene, propylene glycol stearate, wheat germ oil, glyceryl stearate, isopropyl myristate, steryl stearate, polysorbate 60, propylene glycol, oleic acid, tocopherol acetate, collagen, sorbitan stearate, vitamin A & D, triethanolamine, methylparaben, aloe vera extract, imidazolidinyl urea, propylparaben, and BHA.
- L-arginine hydrochloride provides a precursor to the molecule, nitric oxide, NO.
- Nitric oxide is the substance that relaxes the blood vessels, allowing for increased blood flow.
- Choline chloride, sodium chloride and magnesium chloride provides a high ionic strength environment for the highly charged molecule, L-arginine.
- This high ionic strength environment is an example of a hostile biophysical environment for L-arginine. That is, the highly charged ionic strength is an unfavorable environment for the highly charged L-arginine making the L-arginine anxious to move to a more hospitable, less charged environment such as human tissue.
- the base cream containing L-arginine, choline chloride, sodium chloride and magnesium chloride is the agent which produces beneficial effects such as hair growth, healing of ulcers such as leg ulcers or restoration of normal erectile function in males suffering from erectile dysfunction.
- the cream acts effectively to induce hair growth on human scalp lacking sufficient hair when applied nightly to the bald area each night for several months. Hair growth is naturally a slow process. However, substantial hair growth is achieved over large areas of scalp with results becoming evident in a few weeks and substantial within several months. Yet further, the cream acts to promote healing of superficial ulcers such as those sometimes found on the legs of persons with severe diabetes. Application twice daily for a period of two weeks causes substantial healing and in many cases complete healing is achieved within this time period or slightly longer (3-4 weeks). Still further, the cream acts to overcome erectile dysfunction in males causing restoration of natural sexual function. These applications and others share as a common mechanism of action, improvement in local blood flow.
- L-arginine hydrochloride is the preferred active agent because it is the agent in nature itself, it is non-toxic, is highly soluble and it is inexpensive
- other agents could be used which are also precursors or donors of nitric oxide.
- Pharmaceutically acceptable salts include hydrochloride, glutamate, butyrate, and glycolate. L-arginine concentrations desired are 1% to 35%, with 5% to 35% more effective with 12% to 35% best.
- a variety of means for effecting or improving absorption of the active agent can be envisioned.
- One principle behind the absorption of a highly charged molecule such as L-arginine into tissue is to either create a biophysically hostile environment in the delivery vehicle such that L-arginine would prefer to be in tissue, or to package L-arginine in such a way that it is carried into tissue or neutralize its charge by derivitization or forming a neutral salt.
- biophysically hostile environments include but are not limited to; high ionic strength by the addition of ionic salts such as sodium chloride, magnesium chloride or choline chloride; high or low pH by adding pharmaceutically acceptable acids or bases; and highly hydrophobic environments by decreasing water content and increasing lipid; oil and/or wax content.
- Examples of packaging which would be carried into tissue includes liposomes or emulsions of collagen, collagen peptides or other components of skin or basement membrane.
- Examples of neutralization of charge include delivery of the active agent in the form or an ester or salt such as arginine glutamate which is electronically neutral.
- the agent was added to an appropriate preparation.
- ions such as but not limited to sodium chloride, potassium chloride, choline chloride, magnesium chloride, lithium chloride, alone or in combination were added in high concentration.
- Other highly charged molecules such as polylysine, polyglutamine, polyaspartate or copolymers of such charged amino acids may be used to create the hostile biophysical environment.
- a hostile biophysical environment may be created by placing the highly charged L-arginine in an hydrophobic, oily environment such as in an oil-based cream containing little or no water. Absorption may further be aided by combining the use of hostile biophysical environments with the use of penetrating agents such as oleoresin capsicum or its constiutents or molecules containing heterocyclic rings to which are attached hydrocarbon chains.
- a 53 year old man with a scalp lacking sufficient hair consisting of a severely receding hairline as well as large “bald spot” on the top rear of his head was provided with a penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (5% w/v) and magnesium chloride (5% w/v).
- the cream was applied to the bald areas each night before going to bed and was rubbed in extensively for maximal absorption. New hair growth was noted within 2-3 weeks. Within 4 months the receding hairline (previously 4 cm of bald skin) had returned to normal and the “bald spot” previously more than 7 cm in diameter had been reduced to an area of less than 2 cm with even this area showing some new hair growth.
- agents which when applied to scalp lacking sufficient hair causes hair growth through utilization of one of the body's own mechanisms.
- This effect is achieved by providing the biochemical substrate at the local site from which nitric oxide is produced.
- Nitric oxide causes increased local blood flow, which enables the growth of hair.
- agents which when applied to leg ulcers cause healing through use of the body's own mechanisms.
- agents that when applied to a penis subject to erectile dysfunction causes restoration of normal sexual function. This effect is achieved by providing the biochemical substrate at the local site from which the controlling substance, nitric oxide is produced.
- Nitric oxide causes increases in local blood flow allowing the body's own healing cells and substances to reach the ulcer site.
- the treatments for hair loss, impotence and wound and ulcer healing discussed above can be performed with L-arginine or its derivatives without penetrants in a preferred concentration of 5% to 35%, with preferred concentrations greater than 10% with effectiveness greatest at concentration levels above 20%.
- An effective concentration of L-arginine to produce the beneficial effects discussed herein can be reduced when a hostile biophysical environment is created which causes the L-arginine to cross the barrier of the skin.
- the skin barrier is harder to cross than the mucus membranes associated with the anus or inside the mouth or through the lower intestine when taken orally. Therefore to create an effective concentration of L-arginine a sufficient biophysical environment must be created corresponding to the concentration of L-arginine.
- concentration of L-arginine or its derivatives below 5% to 0.25% it is desired to have a concentration of 10% to 90%, preferably from 25% to 75% of an ion donor such as a to create a high ionic strength environment.
- concentration of 5% to 15% of L-arginine or its derivatives it is desired to have a concentration of 5% to 80%, preferably from 15% to 50% of an ion donor such as a to create a high ionic strength environment.
- a method of promoting hair growth, treating impotence or healing wounds comprising delivering a nitric oxide releasing substance selected from a member of the group consisting of L-arginine, L-arginine salts and L-arginine derivatives, to a selected area of the skin where hair growth is desired by topically applying to the selected area of skin where hair growth is desired a delivery vehicle for the substance, said delivery vehicle containing an effective amount of the substance, and a concentration of ionic salt sufficient to create a hostile biophysical environment which causes the substance to migrate from the delivery vehicle to the skin where the substance is absorbed by tissue wherein said delivery vehicle comprises water (20-80%), mineral oil (3-18%), glyceryl stearate (0.5-12%), squalene (0.2-12%), cetyl alcohol (0.1-11%), propylene glycol stearate (0.1-11%), wheat germ oil (0.1-6%) glyceryl stearate (0.1-6%), isopropyl myristate (0.1-6%), stearyl
Abstract
The application of L-arginine and its derivatives to the skin causes beneficial effects of wound healing, increasing erectile function and increased growth of hair when applied in sufficient quantity to the skin. A hostile biophysical agent may be combined with the L-arginine to increase its absorption into the skin. The desired concentrations of the hostile biophysical agent is increased when concentration of L-arginine is less than 20% of the concentration of the substance applied to maximize its effect.
Description
- 1. Field of the Invention
- This invention relates to topical application of a cream, gel, or other vehicle which contains substances such as L-arginine which delivers these substances into tissue for the purpose of producing beneficial effects such as growth of hair on the scalp, healing of leg ulcers secondary to diabetes or confinement to bed and overcoming erectile dysfunction, as well as beneficial effects through restoration of natural mechanisms based on improvement of local blood supply.
- 2. Prior Art
- Approaches to improving local blood flow have been many and consist of both systemic and topical approaches. Many beneficial effects could be obtained should improvement in local blood flow be achieved since impairment of local blood flow causes a variety of negative consequences.
- It has been recognized that deficiencies in blood flow in the scalp occur in male pattern baldness. See G. Duplecnain et al., J. Louisiana State Med. Soc. 146, 7, (1994); P. Klemp et al., J. Invests Dermatol 95, 725 (1989); S Toshitani et al., J. Dermatol 17, 240 (1990). Topical minoxidil has been used as an agent for hair growth in male pattern baldness with varying results. Though the suggestion has been made that minoxidil operates through increase in the blood supply to the scalp, many investigators have failed to show such an effect. See E. de Boer et al., Acta Dermato-Vernereoligica 68, 271 (1988); C Bunker et al., British J Derm 117, 668 (1987).
- It has long been recognized that impaired blood flow to the penis is a major cause of erectile failure (impotence) in men. See A Moradian et al. Am J. Med 85, 748, (1988); T Hwang et al. J. Formosan Med Assoc 89, 992 (1990). Further it has been recognized by using isolated tissue in vitro and in animal experiments that nitric oxide is an important mediator of relaxation of the vessels in penile cavernous tissue. See H Kirkeby et al. Acta Physiol Scand 149, 385 (1993). Topical nitroglycerine has been used in the treatment of impotence because of its ability to dilate vessels. The results were inconclusive and the treatment not well tolerated because of the cardiac response to nitroglycerine. See S Negelev J Urology 143, 586 (1990).
- Accordingly, several objects and advantages of the instant invention are to induce the growth of hair on portions of human scalp which has insufficient hair by means of enhancement of the body's natural mechanisms. It is yet another object of the instant invention to induce healing of superficial ulcers of the limbs by means of enhancement of the body's natural mechanisms. It is still another object of the instant invention to overcome erectile failure restoring natural male sexual function by means of enhancement of the body's own natural mechanisms.
- It was discovered that topical application of a nitric oxide precursor, L-arginine, in its various forms contained in a variety of topical preparations, either by themselves or with other agents to aid in penetration, such as a high ionic strength environment, neutralization of its charge in a complex or by other means, or included in a liposome or other biological carrier, when administered to the scalp causes hair growth, when administered to superficial ulcers causes healing and when administered to the penis enhances erectile function. Increasing the levels of concentration of penetrants in combination with reduced amounts of L-arginine maintains effective treatment concentrations.
- In one embodiment of the invention, a penetrating cream containing L-arginine at an effective concentration and a salt, such as sodium chloride, at a concentration sufficient to create a hostile biophysical environment for the L-arginine in the cream is applied to nightly to the scalp containing a deficit of hair induces hair growth within 3-4 months.
- Further, in accordance with this invention, a penetrating cream containing L-arginine in a concentration sufficient to produce the desired effect along with sodium chloride or other salts at a concentration sufficient to produce a hostile biophysical environment when applied to the penis induces firm and natural erections within 20 minutes.
- Consequently, with the discovery of the present invention, a means to restore hair growth on a portion of scalp scarce in hair has been found. Further, with the discovery of the present invention, a means to heal superficial ulcers has been found. Additionally, with the discovery of the present invention, a means to overcome erectile dysfunction has been found.
- In preferred embodiments, the delivery vehicle is a penetrating cream, the L-arginine is present as L-arginine hydrochloride in a concentration sufficient to produce the desired effect and the agent which creates the hostile biophysical environment is sodium chloride at a concentration sufficient to aid in tissue absorption. L-arginine or its derivatives are present in a concentration of 1% to 35%, with preferred concentrations 5% to 35%, and 12% to 35% better. These and other objects and features of the present invention will become apparent to those skilled in the art from reading the description of the invention, which follows.
- The preferred embodiment consists of a base cream with the properties of excellent absorption into the skin which also contains L-arginine hydrochloride (12.5% w/v), choline chloride (10%), sodium chloride (5% w/v) and magnesium chloride (5% w/v). The components of the base cream may be those commonly found in hand creams, such as water, mineral oil, glyceryl stereate, squalene, propylene glycol stearate, wheat germ oil, glyceryl stearate, isopropyl myristate, steryl stearate, polysorbate 60, propylene glycol, oleic acid, tocopherol acetate, collagen, sorbitan stearate, vitamin A & D, triethanolamine, methylparaben, aloe vera extract, imidazolidinyl urea, propylparaben, and BHA. L-arginine hydrochloride provides a precursor to the molecule, nitric oxide, NO. Nitric oxide is the substance that relaxes the blood vessels, allowing for increased blood flow. Choline chloride, sodium chloride and magnesium chloride provides a high ionic strength environment for the highly charged molecule, L-arginine. This high ionic strength environment is an example of a hostile biophysical environment for L-arginine. That is, the highly charged ionic strength is an unfavorable environment for the highly charged L-arginine making the L-arginine anxious to move to a more hospitable, less charged environment such as human tissue. The base cream containing L-arginine, choline chloride, sodium chloride and magnesium chloride is the agent which produces beneficial effects such as hair growth, healing of ulcers such as leg ulcers or restoration of normal erectile function in males suffering from erectile dysfunction.
- The cream acts effectively to induce hair growth on human scalp lacking sufficient hair when applied nightly to the bald area each night for several months. Hair growth is naturally a slow process. However, substantial hair growth is achieved over large areas of scalp with results becoming evident in a few weeks and substantial within several months. Yet further, the cream acts to promote healing of superficial ulcers such as those sometimes found on the legs of persons with severe diabetes. Application twice daily for a period of two weeks causes substantial healing and in many cases complete healing is achieved within this time period or slightly longer (3-4 weeks). Still further, the cream acts to overcome erectile dysfunction in males causing restoration of natural sexual function. These applications and others share as a common mechanism of action, improvement in local blood flow.
- While L-arginine hydrochloride is the preferred active agent because it is the agent in nature itself, it is non-toxic, is highly soluble and it is inexpensive, other agents could be used which are also precursors or donors of nitric oxide. These include D,L-arginine, L-arginine, alkyl (ethyl, methyl, propyl, isopropyl, butyl, isobutyl, t-butyl) esters of L-arginine and salts thereof. Pharmaceutically acceptable salts include hydrochloride, glutamate, butyrate, and glycolate. L-arginine concentrations desired are 1% to 35%, with 5% to 35% more effective with 12% to 35% best.
- In the case of an alternative active agent were used it would be simply substituted for L-arginine in a delivery preparation and the preparation used as in the case of the L-arginine preparation.
- A variety of means for effecting or improving absorption of the active agent can be envisioned. One principle behind the absorption of a highly charged molecule such as L-arginine into tissue is to either create a biophysically hostile environment in the delivery vehicle such that L-arginine would prefer to be in tissue, or to package L-arginine in such a way that it is carried into tissue or neutralize its charge by derivitization or forming a neutral salt. Examples of biophysically hostile environments, include but are not limited to; high ionic strength by the addition of ionic salts such as sodium chloride, magnesium chloride or choline chloride; high or low pH by adding pharmaceutically acceptable acids or bases; and highly hydrophobic environments by decreasing water content and increasing lipid; oil and/or wax content. Examples of packaging which would be carried into tissue includes liposomes or emulsions of collagen, collagen peptides or other components of skin or basement membrane. Examples of neutralization of charge include delivery of the active agent in the form or an ester or salt such as arginine glutamate which is electronically neutral.
- In each case of creating a hostile biophysical environment for the active agent, the agent was added to an appropriate preparation. In the case of creating a high ionic strength ions such as but not limited to sodium chloride, potassium chloride, choline chloride, magnesium chloride, lithium chloride, alone or in combination were added in high concentration. Other highly charged molecules such as polylysine, polyglutamine, polyaspartate or copolymers of such charged amino acids may be used to create the hostile biophysical environment. Alternatively a hostile biophysical environment may be created by placing the highly charged L-arginine in an hydrophobic, oily environment such as in an oil-based cream containing little or no water. Absorption may further be aided by combining the use of hostile biophysical environments with the use of penetrating agents such as oleoresin capsicum or its constiutents or molecules containing heterocyclic rings to which are attached hydrocarbon chains.
- In this example a 53 year old man with a scalp lacking sufficient hair consisting of a severely receding hairline as well as large “bald spot” on the top rear of his head was provided with a penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (5% w/v) and magnesium chloride (5% w/v). The cream was applied to the bald areas each night before going to bed and was rubbed in extensively for maximal absorption. New hair growth was noted within 2-3 weeks. Within 4 months the receding hairline (previously 4 cm of bald skin) had returned to normal and the “bald spot” previously more than 7 cm in diameter had been reduced to an area of less than 2 cm with even this area showing some new hair growth.
- In a 54 year old man with a history of impotence twice daily administration of a penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (10% w/v) and magnesium chloride (5% w/v) directly to the penis twice daily for 7 days brought initial relief from the symptoms of impotence and allowed the subject to resume normal sexual activity. This relief of symptoms was maintained by continuation of the treatment daily.
- In a 62 year old man with a history of impotence placed a condom containing a water based penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (5% w/v) and magnesium chloride (5% w/v) was warn on the flaccid penis for 30-60 minutes before erection was desired. At that time, when sexual performance was needed, an erection was easily obtained and normal sexual activity was conducted.
- Accordingly, it can be seen that in the present invention I have provided agents, which when applied to scalp lacking sufficient hair causes hair growth through utilization of one of the body's own mechanisms. This effect is achieved by providing the biochemical substrate at the local site from which nitric oxide is produced. Nitric oxide causes increased local blood flow, which enables the growth of hair. Further I have provided agents which when applied to leg ulcers cause healing through use of the body's own mechanisms. Still further I have provided agents that when applied to a penis subject to erectile dysfunction causes restoration of normal sexual function. This effect is achieved by providing the biochemical substrate at the local site from which the controlling substance, nitric oxide is produced. Nitric oxide causes increases in local blood flow allowing the body's own healing cells and substances to reach the ulcer site.
- The treatments for hair loss, impotence and wound and ulcer healing discussed above can be performed with L-arginine or its derivatives without penetrants in a preferred concentration of 5% to 35%, with preferred concentrations greater than 10% with effectiveness greatest at concentration levels above 20%.
- An effective concentration of L-arginine to produce the beneficial effects discussed herein can be reduced when a hostile biophysical environment is created which causes the L-arginine to cross the barrier of the skin. The skin barrier is harder to cross than the mucus membranes associated with the anus or inside the mouth or through the lower intestine when taken orally. Therefore to create an effective concentration of L-arginine a sufficient biophysical environment must be created corresponding to the concentration of L-arginine. With concentration of L-arginine or its derivatives below 5% to 0.25% it is desired to have a concentration of 10% to 90%, preferably from 25% to 75% of an ion donor such as a to create a high ionic strength environment.
- With a concentration of 5% to 15% of L-arginine or its derivatives it is desired to have a concentration of 5% to 80%, preferably from 15% to 50% of an ion donor such as a to create a high ionic strength environment.
- With a concentration of 15% to 25% of L-arginine or its derivatives it is desired to have a concentration of 5% to 50%, preferably from 10% to 30% of an ion donor such as a to create a high ionic strength environment.
- A method of promoting hair growth, treating impotence or healing wounds comprising delivering a nitric oxide releasing substance selected from a member of the group consisting of L-arginine, L-arginine salts and L-arginine derivatives, to a selected area of the skin where hair growth is desired by topically applying to the selected area of skin where hair growth is desired a delivery vehicle for the substance, said delivery vehicle containing an effective amount of the substance, and a concentration of ionic salt sufficient to create a hostile biophysical environment which causes the substance to migrate from the delivery vehicle to the skin where the substance is absorbed by tissue wherein said delivery vehicle comprises water (20-80%), mineral oil (3-18%), glyceryl stearate (0.5-12%), squalene (0.2-12%), cetyl alcohol (0.1-11%), propylene glycol stearate (0.1-11%), wheat germ oil (0.1-6%) glyceryl stearate (0.1-6%), isopropyl myristate (0.1-6%), stearyl stearate (0.1-6%), polysorbate 60 (0.1-5%), propylene glycol (0.05-5%) tocopherol acetate (0.5-5%), collagen (0.05-5%), sorbitan stearate (0.05-5%), vitamin A&D (0.02%-4%), triethanolamine (0.01-4%), methylparaben (0.01-4%), aloe to vera extract (0.01-4%), imidazolidinyl urea (0.01-4%), propylparaben (0.01-4%), bha (0.01-4%), L-arginine hydrochloride (5%-25%), and magnesium chloride (5%-25%) is applied to the selected area of skin where hair growth is desired.
Claims (21)
1-15. (canceled)
16. A composition for application to the skin of a subject, the composition comprising:
a topical cream comprising an L-arginine salt consisting essentially of L-arginine hydrochloride,
wherein the topical cream has a higher salt concentration than does human skin.
17. The composition of claim 16 , wherein the topical cream comprises NaCl at a concentration of at least 10% w/v.
18. The composition of claim 16 , wherein the topical cream further comprises glyceryl stearate.
19. The composition of claim 16 , wherein the topical cream further comprises cetyl alcohol.
20. The composition of claim 16 , wherein the topical cream further comprises squalene.
21. The composition of claim 16 , wherein the topical cream further comprises isopropyl myristate.
22. The composition of claim 16 , wherein the topical cream further comprises oleic acid.
23. The composition of claim 16 , wherein the topical cream further comprises propylene glycol.
24. A composition for application to the skin of a subject, the composition comprising:
a topical cream comprising an L-arginine compound consisting essentially of L-arginine, wherein the topical cream has a higher salt concentration than does human skin.
25. The composition of claim 24 , wherein the topical cream comprises NaCl at a concentration of at least 10% w/v.
26. A method, comprising:
applying to the skin a delivery vehicle comprising L-arginine hydrochloride at a concentration of 0.25% to 25% by weight,
wherein the delivery vehicle further comprises an ion donor present in an amount sufficient to create a high ionic strength environment able to cause the L-arginine hydrochloride to migrate from the delivery vehicle to the skin where the delivery vehicle is applied.
27. The method of claim 26 , wherein (i) said ion donor concentration in the delivery vehicle is 10% to 90% by weight when the concentration of L-arginine hydrochloride in the delivery vehicle is 0.25% to below 5% by weight, (ii) said ion donor concentration in the delivery vehicle is 5% to 80% by weight when the concentration of L-arginine hydrochloride in the delivery vehicle is 5% to 15% by weight, and (iii) said ion donor concentration in the delivery vehicle is 5% to 50% by weight when the concentration of L-arginine hydrochloride in the delivery vehicle is greater than 15% to 25% by weight.
28. The method of claim 26 , wherein the ion donor is selected from the group consisting of sodium chloride, choline chloride, potassium chloride, lithium chloride and magnesium chloride and mixtures thereof.
29. The method of claim 26 , wherein the ion donor comprises NaCl at a concentration of at least 10% w/v.
30. The method of claim 26 , wherein the delivery vehicle is a cream.
31. A topical delivery vehicle for application to the skin comprising:
L-arginine hydrochloride at a concentration of 0.25% to 25% by weight, wherein the ion donor is present in an amount sufficient to create a high ionic strength environment able to cause the L-arginine hydrochloride to migrate from the delivery vehicle to the skin where the delivery vehicle is applied.
32. The topical delivery vehicle of claim 31 , wherein (i) said ion donor concentration in the delivery vehicle is 10% to 90% by weight when the concentration of L-arginine hydrochloride in the delivery vehicle is 0.25% to below 5% by weight, (ii) said ion donor concentration in the delivery vehicle is 5% to 80% by weight when the concentration of L-arginine hydrochloride in the delivery vehicle is 5% to 15% by weight, and (iii) said ion donor concentration in the delivery vehicle is 5% to 50% by weight when the concentration of L-arginine hydrochloride in the delivery vehicle is greater than 15% to 25% by weight.
33. The topical delivery vehicle of claim 31 , wherein the ion donor is selected from the group consisting of sodium chloride, choline chloride, potassium chloride, lithium chloride and magnesium chloride and mixtures thereof.
34. The topical delivery vehicle of claim 31 , wherein the topical delivery vehicle comprises NaCl at a concentration of at least 10% w/v.
35. The topical delivery vehicle of claim 31 , wherein the topical delivery vehicle is a cream.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/833,815 US20100317737A1 (en) | 1997-09-17 | 2010-07-09 | Topical delivery of l-arginine to cause beneficial effects |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/932,227 US7914814B2 (en) | 1997-09-17 | 1997-09-17 | Topical delivery of arginine of cause beneficial effects |
US10/201,635 US7629384B2 (en) | 1997-09-17 | 2002-07-22 | Topical delivery of L-arginine to cause beneficial effects |
US12/608,169 US20100316749A1 (en) | 1997-09-17 | 2009-10-29 | Topical delivery of l-arginine to cause beneficial effects |
US12/833,815 US20100317737A1 (en) | 1997-09-17 | 2010-07-09 | Topical delivery of l-arginine to cause beneficial effects |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/608,169 Continuation US20100316749A1 (en) | 1997-09-17 | 2009-10-29 | Topical delivery of l-arginine to cause beneficial effects |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100317737A1 true US20100317737A1 (en) | 2010-12-16 |
Family
ID=46280902
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/201,635 Expired - Fee Related US7629384B2 (en) | 1997-09-17 | 2002-07-22 | Topical delivery of L-arginine to cause beneficial effects |
US12/608,169 Abandoned US20100316749A1 (en) | 1997-09-17 | 2009-10-29 | Topical delivery of l-arginine to cause beneficial effects |
US12/833,815 Abandoned US20100317737A1 (en) | 1997-09-17 | 2010-07-09 | Topical delivery of l-arginine to cause beneficial effects |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/201,635 Expired - Fee Related US7629384B2 (en) | 1997-09-17 | 2002-07-22 | Topical delivery of L-arginine to cause beneficial effects |
US12/608,169 Abandoned US20100316749A1 (en) | 1997-09-17 | 2009-10-29 | Topical delivery of l-arginine to cause beneficial effects |
Country Status (1)
Country | Link |
---|---|
US (3) | US7629384B2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100280122A1 (en) * | 2004-04-19 | 2010-11-04 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US8603519B2 (en) | 1997-09-17 | 2013-12-10 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US8604081B2 (en) | 2009-06-24 | 2013-12-10 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
US9072659B2 (en) | 2009-06-24 | 2015-07-07 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
US11298453B2 (en) | 2003-10-28 | 2022-04-12 | Smith & Nephew Plc | Apparatus and method for wound cleansing with actives |
JP5376761B2 (en) * | 2004-02-23 | 2013-12-25 | ストラテジック サイエンス アンド テクノロジーズ, エルエルシー | Topical delivery of nitric oxide to improve body and skin appearance |
EP2630960A1 (en) | 2004-04-19 | 2013-08-28 | Strategic Science & Technologies, LLC | Transdermal Delivery of Beneficial Substances Effected by a Hostile Biophysical Environment |
US20110028548A1 (en) * | 2004-04-19 | 2011-02-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20090105336A1 (en) * | 2004-04-19 | 2009-04-23 | Strategic Science & Technologies, Llc | Beneficial Effects of Increasing Local Blood Flow |
US10413644B2 (en) | 2004-04-27 | 2019-09-17 | Smith & Nephew Plc | Wound treatment apparatus and method |
US8529548B2 (en) | 2004-04-27 | 2013-09-10 | Smith & Nephew Plc | Wound treatment apparatus and method |
US7753894B2 (en) | 2004-04-27 | 2010-07-13 | Smith & Nephew Plc | Wound cleansing apparatus with stress |
GB0409446D0 (en) | 2004-04-28 | 2004-06-02 | Smith & Nephew | Apparatus |
HUP0401422A2 (en) | 2004-07-15 | 2006-04-28 | G Laszlo Meszaros | Use of l-arginine as vasoaktive ingredient absorbing through skin for external application |
MX2007007731A (en) * | 2004-12-24 | 2007-10-18 | Dolphst Pty Ltd | Formula ions and treatments for well-being. |
CN102698273A (en) * | 2004-12-24 | 2012-10-03 | 都菲斯特股份有限公司 | Formulations and treatments for trichology |
MX2008002882A (en) | 2005-09-07 | 2008-03-27 | Tyco Healthcare | Wound dressing with vacuum reservoir. |
US9132296B2 (en) | 2007-05-17 | 2015-09-15 | Ag Essence | Antimicrobial solution and methods of making and using the same |
US20130210867A1 (en) * | 2010-04-15 | 2013-08-15 | Life Science Enhancement Corporation | Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction |
US20130022687A1 (en) * | 2011-07-19 | 2013-01-24 | Fitzgerald Jr John James | Topical transdermal method for delivering nutrients through the skin for expedited wound healing |
US11547116B2 (en) * | 2012-12-12 | 2023-01-10 | William Wingfield | Metal oxide compounds and infusion into polymer compounds |
US20160081915A1 (en) | 2013-03-15 | 2016-03-24 | Strategic Science & Technologies, Llc | Transdermal formulations of fluticasone |
EP2968130A1 (en) | 2013-03-15 | 2016-01-20 | Strategic Science & Technologies, LLC | Transdermal delivery of sildenafil and other phosphodiesterase type 5 inhibitors |
US8986732B2 (en) | 2013-08-12 | 2015-03-24 | Helix Biopharma Corporation | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
US10159646B2 (en) | 2013-08-12 | 2018-12-25 | Altum-Avro Pharma Partnership | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
CN103933294B (en) * | 2014-03-25 | 2017-01-04 | 张丽 | A kind of plant extract compositions for sexual dysfunction |
WO2016112201A1 (en) | 2015-01-07 | 2016-07-14 | Strategic Science & Technologies, Llc | Techniques and systems for transdermal delivery involving treatment of psoriasis, skin cancer, and other indications |
US11191735B2 (en) | 2015-03-13 | 2021-12-07 | Nutrition 21, Llc | Arginine silicate for periodontal disease |
US20170135969A1 (en) | 2015-11-12 | 2017-05-18 | Jds Therapeutics, Llc | Topical arginine-silicate-inositol for wound healing |
US10688069B2 (en) | 2016-03-31 | 2020-06-23 | REV Pharmaceuticals LLC | Sports health performance composition |
MX2019002468A (en) | 2016-09-01 | 2019-09-18 | Jds Therapeutics Llc | Magnesium biotinate compositions and methods of use. |
US10456366B2 (en) * | 2017-11-29 | 2019-10-29 | Chiou Consulting, Inc. | Composition and methods for tissue regeneration |
CA3118583A1 (en) | 2018-11-02 | 2020-05-07 | Nutrition 21, Llc | Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers |
WO2021127048A1 (en) | 2019-12-16 | 2021-06-24 | Nutrition 21, Llc | Methods of production of arginine-silicate complexes |
Citations (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3574854A (en) * | 1966-03-22 | 1971-04-13 | Francois J Bossard | Method for soothing the skin with a cream containing sodium chloride |
US3960782A (en) * | 1974-09-27 | 1976-06-01 | The Procter & Gamble Company | Shampoo compositions which impart high luster and manageability to hair |
GB2126868A (en) * | 1982-09-20 | 1984-04-04 | Ralston Purina Co | Method of improving the shelf life of processed meat products |
US4692462A (en) * | 1985-03-18 | 1987-09-08 | Menley & James Laboratories, Ltd. | Compositions and method of controlling transdermal penetration of topical and systemic agents |
US4722837A (en) * | 1984-05-29 | 1988-02-02 | Derma-Cure, Inc. | Medicated shampoo composition |
US4743442A (en) * | 1983-08-02 | 1988-05-10 | Blendax-Werke R. Schneider Gmbh & Co. | Skin care composition |
US4940456A (en) * | 1987-02-10 | 1990-07-10 | Dan Sibalis | Electrolytic transdermal delivery of proteins |
US4945901A (en) * | 1989-03-22 | 1990-08-07 | Burcke Jr Harry J | Hand therapy apparatus and method therefor |
US5008248A (en) * | 1985-11-18 | 1991-04-16 | Beecham Group P.L.C. | Veterinary compositions for the treatment of scours and dehydration |
US5158761A (en) * | 1989-04-05 | 1992-10-27 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
US5215759A (en) * | 1991-10-01 | 1993-06-01 | Chanel, Inc. | Cosmetic composition |
US5217652A (en) * | 1991-10-04 | 1993-06-08 | The Gillette Company | Conditioning shampoo |
US5217997A (en) * | 1990-01-09 | 1993-06-08 | Levere Richard D | Use of l-arginine in the treatment of hypertension and other vascular disorders |
US5256678A (en) * | 1991-05-27 | 1993-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Normal-pentadecyl nicotinate N-oxide and hair restorer comprising the same |
US5464954A (en) * | 1992-08-31 | 1995-11-07 | Idec Izumi Corporation | Safety switch assembly |
US5573776A (en) * | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
US5575994A (en) * | 1991-11-22 | 1996-11-19 | Istituto Gentili S.P.A. | Dermatological and cosmetic compositions |
US5604685A (en) * | 1994-11-11 | 1997-02-18 | Endress Hauser Gmbh Co | Circuit arrangement for the linearization and temperature compensation of sensor signals |
US5645859A (en) * | 1995-10-02 | 1997-07-08 | Isp Investments Inc. | Process for producing an alpha or beta-hydroxy acid-vinylpyrrolidone polymer, copolymer or graft polymer complex in the form of free-flowing powders having a high acid loading |
US5656264A (en) * | 1991-09-10 | 1997-08-12 | Sansyo Seiyaku Co., Ltd. | Method for promoting hair growth |
US5824658A (en) * | 1990-09-18 | 1998-10-20 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
US5985317A (en) * | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
US6264979B1 (en) * | 1994-05-10 | 2001-07-24 | Pal Svedman | Transdermal device for administration through de-epithelialized skin |
US20030044439A1 (en) * | 1998-10-26 | 2003-03-06 | University Of Massachusetts, A Massachusetts Corporation | Treatment of skin with adenosine or adenosine analog |
US20030157185A1 (en) * | 2002-02-08 | 2003-08-21 | Lou Paradise | Topical treatment of neuropathy |
US20030203915A1 (en) * | 2002-04-05 | 2003-10-30 | Xinqin Fang | Nitric oxide donors, compositions and methods of use related applications |
US6642260B2 (en) * | 1997-03-26 | 2003-11-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nitric oxide donors and pharmaceutical compositions containing them |
US6646006B2 (en) * | 1993-06-11 | 2003-11-11 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US6676962B1 (en) * | 1998-07-09 | 2004-01-13 | Lts Lohmann Therapie-Systeme | Topical plaster with non-steroidal antirheumatic agents with an acid group |
US20040228908A1 (en) * | 2003-05-16 | 2004-11-18 | Liu Busang | Topical composition for transdermal administration |
US20050069590A1 (en) * | 2003-09-30 | 2005-03-31 | Buehler Gail K. | Stable suspensions for medicinal dosages |
US20070065463A1 (en) * | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
US20070072847A1 (en) * | 2005-09-29 | 2007-03-29 | Mueller Stephan G | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
US20080045909A1 (en) * | 2004-02-23 | 2008-02-21 | Strategic Science & Technologies, Llc. | Topical Delivery of a Nitric Oxide Donor to Improve and Skin Appearance |
US20080233183A1 (en) * | 2007-03-22 | 2008-09-25 | Pathfinder Management, Inc. | Topical formulations having enhanced bioavailability |
US20080280984A1 (en) * | 2004-04-19 | 2008-11-13 | Strategic Science & Technologies, Llc | Transdermal Delivery of Beneficial Substances Effected By a Hostile Biophysical Environment |
US20080292684A1 (en) * | 2004-07-23 | 2008-11-27 | Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.P.A | Device for Delivery of Active Principles |
US20090105336A1 (en) * | 2004-04-19 | 2009-04-23 | Strategic Science & Technologies, Llc | Beneficial Effects of Increasing Local Blood Flow |
US20090247635A1 (en) * | 2008-03-31 | 2009-10-01 | Eli Ehrenpreis | Method for treating anal pruritis and other perianal disorders |
US20100196332A1 (en) * | 2008-12-10 | 2010-08-05 | Hynek Wichterle | Generation of brachial, thoracic and lumbar spinal motor neurons from embryonic stem cells in the absence of all-trans retinoic acid supplement |
US20100291236A1 (en) * | 2006-08-11 | 2010-11-18 | The University Of Warwick | Osmium compounds |
US20100291195A1 (en) * | 1997-09-17 | 2010-11-18 | Strategic Science & Technologies, Llc | Topical delivery of l-arginine to cause beneficial effects |
US20100316749A1 (en) * | 1997-09-17 | 2010-12-16 | Strategic Science & Technologies, Llc. | Topical delivery of l-arginine to cause beneficial effects |
US20110028548A1 (en) * | 2004-04-19 | 2011-02-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20110182977A1 (en) * | 2009-06-24 | 2011-07-28 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
US20120148665A1 (en) * | 2009-06-24 | 2012-06-14 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
US20120258865A1 (en) * | 2009-03-09 | 2012-10-11 | Bioatla, Llc | Mirac proteins |
US20130289059A1 (en) * | 2004-04-19 | 2013-10-31 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20140004176A1 (en) * | 2010-12-29 | 2014-01-02 | Strategic Science & Techologies | Delivery of treatments transdermally for fungal infections and other indications |
US20140004177A1 (en) * | 2010-12-29 | 2014-01-02 | Strategic Science & Technologies, Llc | Cox-2 inhibitors and related compounds, and systems and methods for delivery thereof |
US20140010866A1 (en) * | 2010-12-29 | 2014-01-09 | Strategic Science & Technologies, Llc | Methods and systems for treatment of migraines and other indications |
US20140038205A1 (en) * | 2011-02-18 | 2014-02-06 | Precision Biologic Inc. | Methods and compositions relating to coagulation assays |
US20140044774A1 (en) * | 2010-12-29 | 2014-02-13 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
US20140051707A1 (en) * | 2010-12-29 | 2014-02-20 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US527997A (en) * | 1894-10-23 | Leaf-turner | ||
FR5940E (en) | 1906-01-30 | 1906-07-27 | Ramier Et Mauberque Soc | Radiator |
FR1553063A (en) | 1967-11-28 | 1969-01-10 | ||
US4185100A (en) * | 1976-05-13 | 1980-01-22 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
GB2094142B (en) | 1981-03-06 | 1984-09-26 | Lab For Applied Biology Ltd | Injectable solution containing theophylline and a basic amino acid |
US4702903A (en) * | 1983-10-03 | 1987-10-27 | Keefer Bowie | Method and apparatus for gas separation and synthesis |
FR2557452B1 (en) * | 1983-12-28 | 1986-08-14 | Roussel Uclaf | NOVEL COMPOSITIONS FOR SKIN CARE CONTAINING PRIMER OIL AND RATE TISSUE TRAITS |
US4681897A (en) * | 1984-01-16 | 1987-07-21 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US4732892A (en) * | 1985-07-12 | 1988-03-22 | American Home Products Corporation | L-α-amino acids as transdermal penetration enhancers |
GB8606368D0 (en) * | 1986-03-14 | 1986-04-23 | Unilever Plc | Skin treatment composition |
FR2602678B1 (en) | 1986-08-13 | 1992-06-05 | Drouault Guy | AQUEOUS PHARMACEUTICAL COMPOSITION BASED ON MAGNESIUM, SODIUM AND POTASSIUM SALTS FOR THE REGULATION OF LOCAL CIRCULATIONS |
US4885157A (en) | 1987-02-13 | 1989-12-05 | Fiaschetti Mary G | Dermal cosmetic composition and applications therefor |
DE3715576A1 (en) * | 1987-05-09 | 1988-11-24 | Wella Ag | NEW MACROMOLECULAR, SURFACE-ACTIVE, QUATERNAIRE N-SUBSTITUTED CHITOSAN DERIVATIVES AND COSMETIC AGENT BASED ON THESE NEW CHITOSAN DERIVATIVES |
US5925372A (en) * | 1987-12-16 | 1999-07-20 | Novartis Corporation | Mixed solvent mutually enhanced transdermal therapeutic system |
US4871718A (en) * | 1987-12-29 | 1989-10-03 | Raymond A. Roncari | Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair |
GB2217595B (en) | 1988-04-21 | 1991-11-20 | American Cyanamid Co | Antiinflammatory gel |
DE3827362A1 (en) * | 1988-08-12 | 1990-02-15 | Basf Ag | POWDERY, HYDROPHILE THEOPHYLINE FORMULATION AND METHOD FOR THE PRODUCTION THEREOF |
EP0406347A4 (en) | 1988-09-30 | 1991-04-03 | Kazuo Watanabe | Anti-inflammatory and analgesic compounds, related compositions and methods for preparation and use thereof |
US5476852A (en) * | 1989-05-03 | 1995-12-19 | Janssen Pharmaceutica N.V. | Method of topically treating acne vulgaris, hyperkeratotic dermatoses, and photo-aging of the skin |
US5028435A (en) * | 1989-05-22 | 1991-07-02 | Advanced Polymer Systems, Inc. | System and method for transdermal drug delivery |
US5576351A (en) * | 1989-12-29 | 1996-11-19 | Mcgaw, Inc. | Use of arginine as an immunostimulator |
JPH045231A (en) | 1990-04-20 | 1992-01-09 | Morishita Pharmaceut Co Ltd | Analgesic for chronic pain |
US5332758A (en) * | 1990-07-13 | 1994-07-26 | Kanebo, Ltd. | Collagen metabolism ameliorant and its use |
WO1992008705A1 (en) | 1990-11-14 | 1992-05-29 | The Upjohn Company | 5-fluoro-2,4,6-pyrimidinetriamine compounds |
DE4100975A1 (en) * | 1991-01-15 | 1992-07-16 | Weuffen Wolfgang | Cosmetic or pharmaceutical preparations for improving hair quality and promoting hair growth |
US5210099A (en) * | 1991-02-11 | 1993-05-11 | American Home Products Corporation | Analgesic compositions |
BR9205713A (en) * | 1991-03-01 | 1994-06-07 | Atherton Investments Ltd | Active ingredient of gastropod secretion, process for its preparation, and composition of active ingredient |
US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
US5254331A (en) | 1991-09-12 | 1993-10-19 | Chanel, Inc. | Skin cream composition |
ATE169826T1 (en) * | 1992-01-21 | 1998-09-15 | Macrochem Corp | IONTOPHORETIC IMPROVED DRUG DELIVERY |
US5405919A (en) * | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
US5632981A (en) * | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US5691423A (en) * | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
GB9222772D0 (en) * | 1992-10-30 | 1992-12-09 | Unilever Plc | Cosmetic composition |
JP3191833B2 (en) | 1993-02-24 | 2001-07-23 | 三菱東京製薬株式会社 | Hair restorer |
US5439938A (en) * | 1993-04-07 | 1995-08-08 | The Johns Hopkins University | Treatments for male sexual dysfunction |
US5852058A (en) | 1993-06-11 | 1998-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
US5428070A (en) * | 1993-06-11 | 1995-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity |
JP3200723B2 (en) | 1993-08-18 | 2001-08-20 | 日本農薬株式会社 | Hair restorer |
DE4338793A1 (en) | 1993-11-12 | 1995-05-18 | Froelich Juergen C | L-arginine and analogues as platelet aggregation inhibitors |
DE4341000A1 (en) | 1993-12-02 | 1995-06-08 | Beiersdorf Ag | Use of L-arginine, L-ornithine or L-citrulline and topical preparations with these substances |
US5714472A (en) * | 1993-12-23 | 1998-02-03 | Nestec Ltd. | Enternal formulation designed for optimized nutrient absorption and wound healing |
US6190704B1 (en) | 1994-09-23 | 2001-02-20 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Regulation of wound healing by nitric oxide |
US5543430A (en) * | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
US5505958A (en) * | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
US5594032A (en) | 1994-11-10 | 1997-01-14 | Gonzalez-Cadavid; Nestor F. | Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA |
US5648101A (en) * | 1994-11-14 | 1997-07-15 | Tawashi; Rashad | Drug delivery of nitric oxide |
US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
US5853768A (en) * | 1995-03-01 | 1998-12-29 | Altadonna; James | Topical preparation and method for pain relief |
US5654337A (en) | 1995-03-24 | 1997-08-05 | II William Scott Snyder | Topical formulation for local delivery of a pharmaceutically active agent |
US5595753A (en) * | 1995-04-14 | 1997-01-21 | President And Fellows Of Harvard College | Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract |
US5698738A (en) * | 1995-05-15 | 1997-12-16 | Board Of Regents, The University Of Texas System | N-nitroso-N-substituted hydroxylamines as nitric oxide donors |
US5762963A (en) | 1995-06-07 | 1998-06-09 | Emory University | Method and compositions for controlling oral and pharyngeal pain using capsaicinoids |
US5605685A (en) * | 1995-09-13 | 1997-02-25 | Isp Investments Inc. | Non-irritating skin and hair rejuvenating compostion having a pH between 1 and 6.5 |
US6036977A (en) * | 1995-09-29 | 2000-03-14 | L.A.M. Pharmaceutical Corp. | Drug preparations for treating sexual dysfunction |
FR2740339B1 (en) * | 1995-10-26 | 1997-12-05 | Oreal | USE OF AT LEAST ONE NO-SYNTHASE INHIBITOR IN THE TREATMENT OF SENSITIVE SKIN |
FR2740453B1 (en) * | 1995-10-27 | 1998-01-16 | Bieurope | PEPTIDE MIXTURES, THEIR PREPARATION AND COSMETIC COMPOSITIONS CONTAINING THEM |
US5789442A (en) * | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
JP4020989B2 (en) * | 1996-03-06 | 2007-12-12 | 株式会社ノエビア | Blood flow promoting agent and external preparation for skin comprising the same |
GB9608408D0 (en) * | 1996-04-23 | 1996-06-26 | Adams Michael A | Treatment of erectile dysfunction |
US5911980A (en) * | 1996-06-27 | 1999-06-15 | Macrochem Corporation | Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin |
US20020015713A1 (en) * | 1996-10-24 | 2002-02-07 | Murdock Robert W. | Methods and transdermal compositions for pain relief |
US5891472A (en) * | 1996-11-19 | 1999-04-06 | Meri Charmyne Russell | Treatment of equine laminitis |
US5807957A (en) * | 1996-12-23 | 1998-09-15 | Macrochem Corporation | Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin |
FR2762782B1 (en) * | 1997-05-05 | 1999-06-11 | Oreal | COMPOSITION COMPRISING A MICROORGANISM CULTURE MEDIUM AND USE THEREOF |
US6232336B1 (en) * | 1997-07-03 | 2001-05-15 | The United States Of America As Represented By The Department Of Health And Human Services | Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same |
US5895658A (en) * | 1997-09-17 | 1999-04-20 | Fossel; Eric T. | Topical delivery of L-arginine to cause tissue warming |
US6207713B1 (en) * | 1997-09-17 | 2001-03-27 | Eric T. Fossel | Topical and oral delivery of arginine to cause beneficial effects |
EP2158907B1 (en) | 1997-09-17 | 2015-08-05 | Strategic Science & Technologies, LLC | Topical administration of arginine for pain treatment |
US5922332A (en) * | 1997-09-17 | 1999-07-13 | Fossel; Eric T. | Topical delivery of arginine to overcome pain |
US6096759A (en) * | 1997-09-19 | 2000-08-01 | Georgetown University | Method for treating essential hypertension |
US5906822A (en) * | 1997-09-25 | 1999-05-25 | Macrochem Corporation | Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin |
US6046244A (en) | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
GB9801398D0 (en) * | 1998-01-22 | 1998-03-18 | Anggard Erik E | Chemical compounds |
IL139907A0 (en) * | 1998-06-01 | 2002-02-10 | Verbiscar Anthony J | Topical transdermal treatments |
US6103275A (en) * | 1998-06-10 | 2000-08-15 | Nitric Oxide Solutions | Systems and methods for topical treatment with nitric oxide |
US6117872A (en) * | 1998-06-23 | 2000-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity |
ATE399565T1 (en) * | 1998-07-07 | 2008-07-15 | Transdermal Technologies Inc | COMPOSITIONS FOR THE RAPID AND NON-IRRITATIVE TRANSDERMAL ADMINISTRATION OF PHARMACEUTICALS AND METHODS OF FORMULATION AND ADMINISTRATION THEREOF |
DE19831798A1 (en) | 1998-07-15 | 2000-01-27 | Mandorlo Investment Gmbh Luxem | Microcirculation improving skin and tissue care or treatment composition, containing salts, aminoacids and peroxide, used as cosmetic, medicament or nutrient supplement |
US6261594B1 (en) * | 1998-11-25 | 2001-07-17 | The University Of Akron | Chitosan-based nitric oxide donor compositions |
FR2787996B1 (en) | 1998-12-30 | 2002-05-10 | Dior Christian Parfums | COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING AN ACTIVE INGREDIENT THAT STIMULATES THE SYNTHESIS OF HSP 32 PROTEIN IN THE SKIN AND COSMETIC PROCESSING METHOD |
AU3490300A (en) | 1999-03-12 | 2000-10-04 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
US6387081B1 (en) * | 1999-03-12 | 2002-05-14 | Mystic Tan, Inc. | Misting apparatus for application of coating materials to skin surface |
US6375672B1 (en) * | 1999-03-22 | 2002-04-23 | Board Of Trustees Of Michigan State University | Method for controlling the chemical and heat induced responses of collagenous materials |
FR2794974B1 (en) * | 1999-06-16 | 2001-08-17 | Exsymol Sa | COSMETIC COMPOSITION FOR SLIMMING BASED ON L-ARGININE, AN ANALOG OF L-ARGININE OR A DERIVATIVE THEREOF, APPLICABLE TOPICALLY |
US6587601B1 (en) * | 1999-06-29 | 2003-07-01 | Sarnoff Corporation | Method and apparatus for performing geo-spatial registration using a Euclidean representation |
KR100876753B1 (en) | 1999-09-07 | 2009-01-07 | 가부시끼가이샤 소껭 | Skin Normalizing Agents |
US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
US6719997B2 (en) * | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
US6565879B1 (en) * | 1999-12-16 | 2003-05-20 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers |
US6602912B2 (en) * | 2000-06-30 | 2003-08-05 | Dermatrends, Inc. | Transdermal administration of phenylpropanolamine |
US6558695B2 (en) * | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
US6562370B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers |
FR2802414B1 (en) | 1999-12-20 | 2003-06-27 | G Pharm Lab | COMPOSITION, ESPECIALLY COSMETIC OR DERMATOLOGICAL, CONTAINING OLIGOSACCHARIDES, METHOD FOR THE PREPARATION THEREOF AND METHOD FOR THE COSMETIC TREATMENT |
FR2810540B1 (en) | 2000-06-21 | 2004-04-30 | C3D | NEW COSMETIC OR HYGIENIC PREPARATIONS IN THE FORM OF DISPERSION |
US6538033B2 (en) * | 2000-08-29 | 2003-03-25 | Huntington Medical Research Institutes | Nitric oxide donor compounds |
EP1359885A4 (en) | 2001-01-25 | 2005-03-16 | Gen Hospital Corp | Nos inhibitors for treatment of wrinkles |
DE10128910A1 (en) | 2001-06-15 | 2002-12-19 | Beiersdorf Ag | Combination of arginine and ascorbic acid is used in the production of cosmetic or dermatological compositions for tightening and/or strengthening the skin, especially in cellulite treatment |
US20020168424A1 (en) * | 2002-07-31 | 2002-11-14 | Dr. Mohsen Shahinpoor | Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma |
US7241456B2 (en) * | 2002-10-25 | 2007-07-10 | Australian Importers Ltd. | Formulations for topical delivery of bioactive substances and methods for their use |
AU2003903037A0 (en) * | 2003-06-17 | 2003-07-03 | Institute Of Nutraceutical Research | Connective tissue derived polypeptides |
-
2002
- 2002-07-22 US US10/201,635 patent/US7629384B2/en not_active Expired - Fee Related
-
2009
- 2009-10-29 US US12/608,169 patent/US20100316749A1/en not_active Abandoned
-
2010
- 2010-07-09 US US12/833,815 patent/US20100317737A1/en not_active Abandoned
Patent Citations (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3574854A (en) * | 1966-03-22 | 1971-04-13 | Francois J Bossard | Method for soothing the skin with a cream containing sodium chloride |
US3960782A (en) * | 1974-09-27 | 1976-06-01 | The Procter & Gamble Company | Shampoo compositions which impart high luster and manageability to hair |
GB2126868A (en) * | 1982-09-20 | 1984-04-04 | Ralston Purina Co | Method of improving the shelf life of processed meat products |
US4743442A (en) * | 1983-08-02 | 1988-05-10 | Blendax-Werke R. Schneider Gmbh & Co. | Skin care composition |
US4722837A (en) * | 1984-05-29 | 1988-02-02 | Derma-Cure, Inc. | Medicated shampoo composition |
US4692462A (en) * | 1985-03-18 | 1987-09-08 | Menley & James Laboratories, Ltd. | Compositions and method of controlling transdermal penetration of topical and systemic agents |
US5008248A (en) * | 1985-11-18 | 1991-04-16 | Beecham Group P.L.C. | Veterinary compositions for the treatment of scours and dehydration |
US4940456A (en) * | 1987-02-10 | 1990-07-10 | Dan Sibalis | Electrolytic transdermal delivery of proteins |
US4945901A (en) * | 1989-03-22 | 1990-08-07 | Burcke Jr Harry J | Hand therapy apparatus and method therefor |
US5158761A (en) * | 1989-04-05 | 1992-10-27 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
US5217997A (en) * | 1990-01-09 | 1993-06-08 | Levere Richard D | Use of l-arginine in the treatment of hypertension and other vascular disorders |
US5824658A (en) * | 1990-09-18 | 1998-10-20 | Hyal Pharmaceutical Corporation | Topical composition containing hyaluronic acid and NSAIDS |
US5256678A (en) * | 1991-05-27 | 1993-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Normal-pentadecyl nicotinate N-oxide and hair restorer comprising the same |
US5656264A (en) * | 1991-09-10 | 1997-08-12 | Sansyo Seiyaku Co., Ltd. | Method for promoting hair growth |
US5215759A (en) * | 1991-10-01 | 1993-06-01 | Chanel, Inc. | Cosmetic composition |
US5217652A (en) * | 1991-10-04 | 1993-06-08 | The Gillette Company | Conditioning shampoo |
US5575994A (en) * | 1991-11-22 | 1996-11-19 | Istituto Gentili S.P.A. | Dermatological and cosmetic compositions |
US5464954A (en) * | 1992-08-31 | 1995-11-07 | Idec Izumi Corporation | Safety switch assembly |
US5573776A (en) * | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
US6646006B2 (en) * | 1993-06-11 | 2003-11-11 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US20040082659A1 (en) * | 1993-06-11 | 2004-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US6264979B1 (en) * | 1994-05-10 | 2001-07-24 | Pal Svedman | Transdermal device for administration through de-epithelialized skin |
US5604685A (en) * | 1994-11-11 | 1997-02-18 | Endress Hauser Gmbh Co | Circuit arrangement for the linearization and temperature compensation of sensor signals |
US5645859A (en) * | 1995-10-02 | 1997-07-08 | Isp Investments Inc. | Process for producing an alpha or beta-hydroxy acid-vinylpyrrolidone polymer, copolymer or graft polymer complex in the form of free-flowing powders having a high acid loading |
US5985317A (en) * | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
US6642260B2 (en) * | 1997-03-26 | 2003-11-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nitric oxide donors and pharmaceutical compositions containing them |
US20140072618A1 (en) * | 1997-09-17 | 2014-03-13 | Strategic Science & Technologies, Llc | Topical delivery of l-arginine to cause beneficial effects |
US20100291195A1 (en) * | 1997-09-17 | 2010-11-18 | Strategic Science & Technologies, Llc | Topical delivery of l-arginine to cause beneficial effects |
US20100316749A1 (en) * | 1997-09-17 | 2010-12-16 | Strategic Science & Technologies, Llc. | Topical delivery of l-arginine to cause beneficial effects |
US7914814B2 (en) * | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
US8603519B2 (en) * | 1997-09-17 | 2013-12-10 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US20140066511A1 (en) * | 1997-09-17 | 2014-03-06 | Strategic Science & Technologies, Llc | Topical delivery of l-arginine to cause beneficial effects |
US6676962B1 (en) * | 1998-07-09 | 2004-01-13 | Lts Lohmann Therapie-Systeme | Topical plaster with non-steroidal antirheumatic agents with an acid group |
US20030044439A1 (en) * | 1998-10-26 | 2003-03-06 | University Of Massachusetts, A Massachusetts Corporation | Treatment of skin with adenosine or adenosine analog |
US20030157185A1 (en) * | 2002-02-08 | 2003-08-21 | Lou Paradise | Topical treatment of neuropathy |
US20030203915A1 (en) * | 2002-04-05 | 2003-10-30 | Xinqin Fang | Nitric oxide donors, compositions and methods of use related applications |
US20040228908A1 (en) * | 2003-05-16 | 2004-11-18 | Liu Busang | Topical composition for transdermal administration |
US20070065463A1 (en) * | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
US20050069590A1 (en) * | 2003-09-30 | 2005-03-31 | Buehler Gail K. | Stable suspensions for medicinal dosages |
US20080045909A1 (en) * | 2004-02-23 | 2008-02-21 | Strategic Science & Technologies, Llc. | Topical Delivery of a Nitric Oxide Donor to Improve and Skin Appearance |
US20100196517A1 (en) * | 2004-02-23 | 2010-08-05 | Strategic Science & Technologies, Llc | Topical delivery of a nitric oxide donor to improve body and skin appearance |
US20120108664A1 (en) * | 2004-04-19 | 2012-05-03 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US20130289059A1 (en) * | 2004-04-19 | 2013-10-31 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20090221536A1 (en) * | 2004-04-19 | 2009-09-03 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US20100280122A1 (en) * | 2004-04-19 | 2010-11-04 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US20090123528A1 (en) * | 2004-04-19 | 2009-05-14 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US20090105336A1 (en) * | 2004-04-19 | 2009-04-23 | Strategic Science & Technologies, Llc | Beneficial Effects of Increasing Local Blood Flow |
US20110028548A1 (en) * | 2004-04-19 | 2011-02-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20080280984A1 (en) * | 2004-04-19 | 2008-11-13 | Strategic Science & Technologies, Llc | Transdermal Delivery of Beneficial Substances Effected By a Hostile Biophysical Environment |
US20140066452A1 (en) * | 2004-04-19 | 2014-03-06 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US20080292684A1 (en) * | 2004-07-23 | 2008-11-27 | Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.P.A | Device for Delivery of Active Principles |
US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
US20070072847A1 (en) * | 2005-09-29 | 2007-03-29 | Mueller Stephan G | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
US20100291236A1 (en) * | 2006-08-11 | 2010-11-18 | The University Of Warwick | Osmium compounds |
US20080233183A1 (en) * | 2007-03-22 | 2008-09-25 | Pathfinder Management, Inc. | Topical formulations having enhanced bioavailability |
US20090247635A1 (en) * | 2008-03-31 | 2009-10-01 | Eli Ehrenpreis | Method for treating anal pruritis and other perianal disorders |
US20100196332A1 (en) * | 2008-12-10 | 2010-08-05 | Hynek Wichterle | Generation of brachial, thoracic and lumbar spinal motor neurons from embryonic stem cells in the absence of all-trans retinoic acid supplement |
US20120258865A1 (en) * | 2009-03-09 | 2012-10-11 | Bioatla, Llc | Mirac proteins |
US20140056971A1 (en) * | 2009-06-24 | 2014-02-27 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US8604081B2 (en) * | 2009-06-24 | 2013-12-10 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
US20140086980A1 (en) * | 2009-06-24 | 2014-03-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US20140073697A1 (en) * | 2009-06-24 | 2014-03-13 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US20110182977A1 (en) * | 2009-06-24 | 2011-07-28 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
US20120148665A1 (en) * | 2009-06-24 | 2012-06-14 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
US20140004177A1 (en) * | 2010-12-29 | 2014-01-02 | Strategic Science & Technologies, Llc | Cox-2 inhibitors and related compounds, and systems and methods for delivery thereof |
US20140051717A1 (en) * | 2010-12-29 | 2014-02-20 | Strategic Science & Technologies, Llc | Methods and systems for treatment of migraines and other indications |
US20140051707A1 (en) * | 2010-12-29 | 2014-02-20 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US20140044774A1 (en) * | 2010-12-29 | 2014-02-13 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
US20140010866A1 (en) * | 2010-12-29 | 2014-01-09 | Strategic Science & Technologies, Llc | Methods and systems for treatment of migraines and other indications |
US20140004176A1 (en) * | 2010-12-29 | 2014-01-02 | Strategic Science & Techologies | Delivery of treatments transdermally for fungal infections and other indications |
US20140038205A1 (en) * | 2011-02-18 | 2014-02-06 | Precision Biologic Inc. | Methods and compositions relating to coagulation assays |
Non-Patent Citations (1)
Title |
---|
Flick, E.W. Cosmetic and Toiletry Formulations. 2nd ed., Noyes Publications, Park Ridge, NJ, 1989, Vol. 1, pages 234, 237. * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8603519B2 (en) | 1997-09-17 | 2013-12-10 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20100280122A1 (en) * | 2004-04-19 | 2010-11-04 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US9050365B2 (en) | 2004-04-19 | 2015-06-09 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9737543B2 (en) | 2009-06-24 | 2017-08-22 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9161915B2 (en) | 2009-06-24 | 2015-10-20 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US9072659B2 (en) | 2009-06-24 | 2015-07-07 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9457092B2 (en) | 2009-06-24 | 2016-10-04 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US8604081B2 (en) | 2009-06-24 | 2013-12-10 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
US9492458B2 (en) | 2009-06-24 | 2016-11-15 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US10898489B2 (en) | 2009-06-24 | 2021-01-26 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9675619B2 (en) | 2009-06-24 | 2017-06-13 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9155701B2 (en) | 2009-06-24 | 2015-10-13 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US10682357B2 (en) | 2009-06-24 | 2020-06-16 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US10172865B2 (en) | 2009-06-24 | 2019-01-08 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9833456B2 (en) | 2010-12-29 | 2017-12-05 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9498482B2 (en) | 2010-12-29 | 2016-11-22 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
Also Published As
Publication number | Publication date |
---|---|
US7629384B2 (en) | 2009-12-08 |
US20100316749A1 (en) | 2010-12-16 |
US20030028169A1 (en) | 2003-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7629384B2 (en) | Topical delivery of L-arginine to cause beneficial effects | |
US8603519B2 (en) | Topical delivery of L-arginine to cause beneficial effects | |
US6458841B2 (en) | Topical and oral delivery of arginine to cause beneficial effects | |
AU737199B2 (en) | A delivery of arginine to cause beneficial effects | |
US5895658A (en) | Topical delivery of L-arginine to cause tissue warming | |
US5922332A (en) | Topical delivery of arginine to overcome pain | |
EP1732577B1 (en) | Topical delivery of l-arginine to improve body and skin appearance | |
CA2023810C (en) | Pharmaceutical composition | |
US5425954A (en) | Topical amino acid - vitamin complex compositions for pharmaceutical and cosmetic use | |
US5629002A (en) | Cosmetic or pharmaceutic preparations for improving hair quaility and stimulating growth of the hair | |
EP1317309B1 (en) | Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant | |
JP2002515401A5 (en) | ||
US20090123528A1 (en) | Transdermal delivery of beneficial substances effected by a hostile biophysical environment | |
KR19990082254A (en) | Traniste-containing external preparation and its manufacturing method | |
CA2551690A1 (en) | Compositions for use with skin | |
JPH10306030A (en) | External preparation composition | |
US20040258774A1 (en) | Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of a 5-phosphodiaesterase inhibitor for the treatment of female sexual dysfunction | |
JPH1129461A (en) | Skin cosmetic containing hydroxyaspartic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: STRATEGIC SCIENCE & TECHNOLOGIES, LLC, MASSACHUSET Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FOSSEL, ERIC THOR;REEL/FRAME:024685/0174 Effective date: 20050923 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |